No Data
No Data
United Therapeutics(UTHR.US) Director Sells US$1.98 Million in Common Stock
$United Therapeutics(UTHR.US)$ Director ROTHBLATT MARTINE A sold 7,200 shares of common stock on May 20, 21, 2024 at an average price of $274.9683 for a total value of $1.98 million.Source: Announceme
Expert Ratings For United Therapeutics
During the last three months, 7 analysts shared their evaluations of United Therapeutics (NASDAQ:UTHR), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent
United Therapeutics Is Maintained at Overweight by JP Morgan
United Therapeutics Is Maintained at Overweight by JP Morgan
Komo: Maintaining the United Therapeutics (UTHR.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $280.00 to $300.00.
Komo: Maintaining the United Therapeutics (UTHR.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $280.00 to $300.00.
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $280 to $300.
United Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 9.02% JP Morgan $280 → $300 Maintains Overweight 05/03/2024 -12.79% Goldman Sachs $218 → $240 M